通策医疗股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600763 证券简称：通策医疗 公告编号：2025-013 会议召开时间：2025 年 06 月 24 日（星期二）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 06 月 17 日（星期二）至 06 月 23 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lianghao@eetop.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 https://roadshow.sseinfo.com/） 二、说明会召开的时间、地点 通策医疗股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发布公 司 2024 年度报告、2025 年一季度报告，为便于广大投资者更全面深入地了解公 司 20 ...

Summary of Key Points Core Viewpoint - Tongce Medical (600763) has experienced a slight decline in stock price, closing at 41.47 CNY as of June 13, 2025, down 1.14% from the previous week, with a total market capitalization of 18.549 billion CNY [1] Company Announcements - The company announced a cash dividend of 0.45 CNY per share, to be distributed on June 18, 2025 [1] - The record date for the dividend is June 17, 2025, with the ex-dividend date also set for June 18, 2025 [1] - The total cash dividend payout amounts to approximately 201.28 million CNY, based on a total share capital of 447,289,117 shares [1] - Different tax policies apply to individual shareholders and institutional investors based on their holding periods and types [1]

Core Viewpoint - The company has announced a cash dividend of 0.45 CNY per share, totaling approximately 201.28 million CNY, to be distributed to shareholders [2][3][5]. Dividend Distribution Details - The cash dividend distribution was approved at the annual general meeting held on June 5, 2025 [2]. - The total number of shares for the dividend calculation is 447,289,117 shares [2]. - The key dates for the dividend distribution are as follows: - Record date: June 17, 2025 - Last trading date: June 18, 2025 - Ex-dividend date: June 18, 2025 [2]. Taxation Information - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax [3]. - For shares held for one month or less, 50% of the dividend is included in taxable income, subject to a 20% tax rate [3][5]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax applies, resulting in a net dividend of 0.405 CNY per share after tax [6]. - For Hong Kong investors, the same 10% withholding tax applies, leading to a net dividend of 0.405 CNY per share [6]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Securities Affairs Department at 0571-88868808 [5].

证券代码：600763 证券简称：通策医疗 公告编号：2025-012 通策医疗股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.45元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/17 | － | 2025/6/18 | 2025/6/18 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 5 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本447,289,117股为基数，每股派发 ...

截至2025年6月6日收盘，通策医疗(600763)报收于41.95元，下跌0.43%，换手率0.84%，成交量3.77万 手，成交额1.59亿元。 会议审议通过了七项非累积投票议案，包括：1. 2024年年度报告2. 董事会工作报告3. 监事会工作报告4. 2024年度利润分配方案5. 2024年度财务决算报告6. 续聘会计师事务所议案7. 修订公司章程议案 各议案均获得高比例支持，具体表决情况见公告。现金分红分段表决结果显示，持股5%以上和1%-5% 的普通股股东全部同意，持股1%以下普通股股东中89.2999%同意。涉及重大事项时，5%以下股东对利 润分配方案、续聘会计师事务所和修订公司章程议案的支持率分别为97.3250%、97.3024%和 97.1902%。 浙江天册律师事务所朱纯怡律师和李沛雨律师见证了本次股东大会，并认为会议合法有效。 浙江天册律师事务所为通策医疗股份有限公司2024年年度股东大会出具法律意见书，认为本次股东大会 的召集与召开程序、出席会议人员的资格、会议表决程序均符合法律法规和公司章程规定，表决结果合 法有效。 当日关注点 交易信息汇总 6月6日，通策医疗的资金流向显示，主力 ...

Core Viewpoint - Tongce Medical (600763) has shown a positive stock performance, closing at 41.95 CNY, a 1.52% increase from the previous week, with a total market capitalization of 18.764 billion CNY [1] Company Announcements - The 2024 Annual General Meeting of Tongce Medical was successfully held on June 5, 2025, with 595 attendees representing 36.5312% of the voting shares [1] - Seven non-cumulative voting resolutions were approved during the meeting, including the 2024 annual report, board work report, supervisory board work report, profit distribution plan, financial settlement report, reappointment of accounting firm, and amendments to the company’s articles of association [1][3] - The voting results showed high support for all resolutions, with significant backing from shareholders holding more than 5% and 1%-5% of shares, and 89.2999% support from shareholders holding less than 1% [2] Legal Compliance - The meeting was witnessed by lawyers from Zhejiang Tiance Law Firm, confirming that the meeting was legally valid and complied with relevant laws and company regulations [2][3]

Meeting Overview - The shareholders' meeting of Tongce Medical Co., Ltd. was held on June 5, 2025, at the company's headquarters in Hangzhou [1] - The meeting was convened by the board of directors and chaired by Chairwoman Wang Yi, following legal and procedural requirements [1] Voting Results - All proposed resolutions were approved by the shareholders, with significant support from A-shareholders [2][3] - The voting results for the annual report showed 99.7649% approval from A-shareholders, with only 0.1801% against and 0.0550% abstaining [1] - The cash dividend proposal received 99.7415% approval, with 0.1908% against and 0.0677% abstaining [2] Shareholder Participation - The meeting included participation from various shareholder categories, with 100% approval from major shareholders holding over 5% of shares [2] - Among shareholders holding less than 1%, 89.2999% voted in favor of the proposals, indicating strong support from smaller investors [2] Legal Compliance - The meeting was witnessed by lawyers from Zhejiang Tian Ce Law Firm, confirming that the meeting's procedures and voting were in compliance with legal and regulatory standards [3]

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the annual general meeting of Tongce Medical Co., Ltd. for 2024 [1][2][6] Group 1: Meeting Procedures - The annual general meeting was proposed and convened by the board of directors, with the notice published on May 15, 2025 [2][3] - The meeting utilized a combination of on-site and online voting, with the on-site meeting scheduled for June 5, 2025, at 14:30 [2][3] - The online voting period was set for June 5, 2025, from 9:15 to 15:00 [3] Group 2: Attendance and Voting - Attendees included all registered shareholders from the Shanghai branch, with the option to appoint proxies who do not need to be shareholders [3][4] - A total of 3 individuals attended the meeting in person, representing 159,642,160 shares, approximately 35.6910% of the total share capital [4] - The total number of participants in the voting, including both on-site and online, was 595, representing 163,400,082 shares, approximately 36.5312% of the total share capital [4] Group 3: Voting Results - The voting process adhered to legal and regulatory requirements, with results announced on-site without objections from attendees [6] - The voting results for various proposals showed overwhelming support, with approval rates ranging from 99.7317% to 99.7649% [5][6] - The meeting did not vote on any matters not listed in the notice [6] Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance qualifications, and voting procedures complied with relevant laws and regulations, confirming the validity of the voting results [6]

证券代码：600763 证券简称：通策医疗 公告编号：2025-011 通策医疗股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 595 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,400,082 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 36.5312 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王毅女士主持本次股东大会。会议的召 开程序、表决方式等符合《公司法》及《公司章程》的有关规定。本次会议采取 现场结合网络的表决方式。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； 有限公司 2024 年年度报告摘要》 2、 ...

法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0805 号 致：通策医疗股份有限公司 浙江天册律师事务所（以下简称"本所"）接受通策医疗股份有限公司（以 下简称"通策医疗"或"公司"）的委托，指派本所律师参加贵公司 2024 年年 度股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和 其他有关规范性文件的要求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和该等议案中所表述的事实或数据 的真实性和准确性发表意见。 本法律意见书仅供 2024 年年度股东大会之 ...